CBT for tinnitus related insomnia

Cognitive Behavior Therapy for tinnitus related insomnia: a single-case experiment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON24403

Enrollment

Registered

2019-06-24

Start date

2019-07-01

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Tinnitus

Interventions

Cognitive Behavior Therapy for Insomnia (CBTi)

Eligibility

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Be primarily seeking treatment/help for difficulties caused by tinnitus. - Additionally complaints of sleep disturbance (e.g. insomnia) as measured by the Insomnia Severity Index. - Recommended to start CBTi protocol. - Be at least 18 years of age. - Have at least moderate tinnitus (as defined by the Tinnitus Questionnaire)

Exclusion criteria

Exclusion criteria: - Any person who discloses current suicidal intent. - Severe anxiety or depression (as measured by the HADS-A and/or HADS-D.) - Pregnancy of potential participant or partner. - Currently undergoing any treatment for tinnitus (e.g. Tinnitus Retraining Therapy). - Reported to have commenced or ceased a course of antidepressants [i.e. selective serotonin re-uptake inhibitors (SSRIs); selective serotonin and norepinephrine re-uptake inhibitors (SNRIs); atypical antidepressants, tricyclic antidepressants, or monoamine oxidase inhibitors], antipsychotics [Aripiprazole (Abilify), Asenapine (Saphris), Brexpiprazole (Rexulti), Cariprazine (Vraylar), Clozapine (Clozaril), Iloperidone (Fanapt), Lurasidone (Latuda), Olanzapine (Zyprexa), Paliperidone (Invega), Quetiapine (Seroquel), Risperidone (Risperdal), Ziprasidone (Geodon), Haloperidol], anxioltytics [beta blockers, benzodiazepines], Ritalin, hormone replacement therapy, or medication to lower high blood pressure (i.e. thiazide diuretics, ACE inhibitors, angiotensin II receptor blockers, beta blockers, calcium channel blockers, renin inhibitors] within the previous 3 months - Unable to read and write fluently in Dutch.

Design outcomes

Primary

Measure	Time frame
Sleep quality as measured by the sleep diary	—

Secondary

Measure	Time frame
Tinnitus experience as measured by the tinnitus diary	—

Contacts

Public ContactMatheus Lourenco

Maastricht University

matheus.lourenco@maastrichtuniversity.nl+31 (0) 4 33 88 24 68

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)